Meeting
2020 ASCO Virtual Scientific Program
Pharmacodynamic, safety, and efficacy results of a phase I/II trial of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab (PEM) (Keynote A10) in patients with advanced solid tumors.
Authors
Jacob Stephen Thomas
USC Norris Comprehensive Cancer Center, Los Angeles, CA
Jacob Stephen Thomas , Anthony B. El-Khoueiry , Ian B. Walters , Nilofer Saba Azad , Lewis H. Bender , Diana L. Hanna , Giles Francis Whalen , Anthony J. Olszanski , Lillian L. Siu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
03058289
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3016)
DOI
10.1200/JCO.2020.38.15_suppl.3016
Abstract #
3016
Poster Bd #
80
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
![Effect of intratumoral INT230-6 on tumor necrosis and promotion of a systemic immune response: Results from a multicenter phase 1/2 study of solid tumors with and without pembrolizumab (PEM) [Intensity IT-01; Merck KEYNOTE-A10].](https://d201v5jt9ylckg.cloudfront.net/288/14354/207587/207587_A1412_poster_pv.jpg)
Effect of intratumoral INT230-6 on tumor necrosis and promotion of a systemic immune response: Results from a multicenter phase 1/2 study of solid tumors with and without pembrolizumab (PEM) [Intensity IT-01; Merck KEYNOTE-A10].
First Author: Jacob Stephen Thomas
Poster
2021 ASCO Annual Meeting
![A phase 1/2 study of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab [KEYNOTE-A10] in adult subjects with locally advanced, unresectable and metastatic solid tumors refractory to therapy.](https://d201v5jt9ylckg.cloudfront.net/273/13618/196128/196128_A711_poster_pv.jpg)
A phase 1/2 study of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab [KEYNOTE-A10] in adult subjects with locally advanced, unresectable and metastatic solid tumors refractory to therapy.
First Author: Anthony B. El-Khoueiry
Poster
2018 ASCO Annual Meeting
An open label phase I study to evaluate the safety and efficacy of OBP-301 with pembrolizumab in patients with advanced solid tumors.
First Author: Takashi Kojima
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang